Revelation Biosciences Inc Market Cap ($4.02 Million)
Market Cap & Net Worth: Revelation Biosciences Inc (REVB)
Revelation Biosciences Inc market cap. Revelation Biosciences Inc (NASDAQ:REVB) has a market capitalization of $4.02 Million ($4.02 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28943 globally and #5939 in its home market, demonstrating a 25.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revelation Biosciences Inc's stock price $4.43 by its total outstanding shares 3983416 (3.98 Million). Also see REVB operating cash flow for how efficiently the company converts equity into cash flow.
Revelation Biosciences Inc Market Cap History (2020–2026)
Revelation Biosciences Inc market cap history from 2020 to 2026. Data shows change from $42.03 Billion to $17.65 Million (-72.71% CAGR). Check latest Revelation Biosciences Inc stock price today for real-time trading data and today's change.
Index Memberships
Revelation Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #836 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2666 of 3165 |
Weight: Revelation Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Revelation Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revelation Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore REVB net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of REVB by Market Capitalization
Companies near Revelation Biosciences Inc in the global market cap rankings as of November 4, 2026. Also see Revelation Biosciences Inc (REVB) total assets for a full breakdown of the balance sheet.
Key companies related to Revelation Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Revelation Biosciences Inc (2020–2026)
Market capitalization of Revelation Biosciences Inc from 2020 to today. Between 2020 and today, Revelation Biosciences Inc's market cap moved from $42.03 Billion to $ 17.65 Million, with a yearly change of -72.71%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $17.65 Million | +453.89% |
| 2025 | $3.19 Million | +73.49% |
| 2024 | $1.84 Million | -96.93% |
| 2023 | $59.83 Million | -92.47% |
| 2022 | $795.11 Million | -98.14% |
| 2021 | $42.66 Billion | +1.49% |
| 2020 | $42.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Revelation Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.02 Million USD |
| MoneyControl | $4.02 Million USD |
| MarketWatch | $4.02 Million USD |
| marketcap.company | $4.02 Million USD |
| Reuters | $4.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more